Abstract |
Merck Serono SA, under license from Genmab A/S and Medarex Inc, is developing zanolimumab, a human mAb targeted against CD4, for the potential treatment of cutaneous (CTCL) and noncutaneous (NCTCL) T-cell lymphomas. Zanolimumab is currently undergoing phase III clinical trials for CTCL and phase II clinical trials for NCTCL.
|
Authors | Chalid Assaf, Wolfram Sterry |
Journal | Current opinion in molecular therapeutics
(Curr Opin Mol Ther)
Vol. 9
Issue 2
Pg. 197-203
(Apr 2007)
ISSN: 1464-8431 [Print] England |
PMID | 17458175
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- CD4 Antigens
- zanolimumab
|
Topics |
- Antibodies, Monoclonal
(adverse effects, pharmacokinetics, pharmacology)
- Antibodies, Monoclonal, Humanized
- CD4 Antigens
(immunology)
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Contraindications
- Drug Evaluation, Preclinical
- Humans
- Patents as Topic
- Structure-Activity Relationship
|